Difference between revisions of "Lipefilgrastim (Lonquex)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Jwarner moved page Lipefilgrastim (XM22) to Lipefilgrastim (Lonquex): EMA approval)
m
 
(2 intermediate revisions by the same user not shown)
Line 2: Line 2:
 
From NCI: "A long acting glyco-pegylated recombinant form of human granulocyte colony-stimulating factor (G-CSF), with hematopoietic activity. Similar to G-CSF, lipegfilgrastim binds to and activates specific cell surface receptors, and stimulates neutrophil progenitor proliferation and differentiation."
 
From NCI: "A long acting glyco-pegylated recombinant form of human granulocyte colony-stimulating factor (G-CSF), with hematopoietic activity. Similar to G-CSF, lipegfilgrastim binds to and activates specific cell surface receptors, and stimulates neutrophil progenitor proliferation and differentiation."
  
 +
==History of changes in EMA indication==
 +
*2013-07-25: Initial authorization
 
==Also known as==
 
==Also known as==
 
*'''Code name:''' XM22
 
*'''Code name:''' XM22
 +
*'''Brand name:''' Lonquex
  
 
[[Category:Drugs]]
 
[[Category:Drugs]]
Line 9: Line 12:
 
[[Category:Subcutaneous medications]]
 
[[Category:Subcutaneous medications]]
 
[[Category:Granulocyte colony-stimulating factors]]
 
[[Category:Granulocyte colony-stimulating factors]]
[[Category:Investigational drugs]]
+
[[Category:Recombinant medications]]
 +
 
 +
[[Category:EMA approved in 2013]]
 
[[Category:Stub]]
 
[[Category:Stub]]

Latest revision as of 14:34, 28 February 2024

Mechanism of action

From NCI: "A long acting glyco-pegylated recombinant form of human granulocyte colony-stimulating factor (G-CSF), with hematopoietic activity. Similar to G-CSF, lipegfilgrastim binds to and activates specific cell surface receptors, and stimulates neutrophil progenitor proliferation and differentiation."

History of changes in EMA indication

  • 2013-07-25: Initial authorization

Also known as

  • Code name: XM22
  • Brand name: Lonquex